PL2591798T3 - Szczepionka do zastosowania w immunoterapii nowotworów - Google Patents

Szczepionka do zastosowania w immunoterapii nowotworów

Info

Publication number
PL2591798T3
PL2591798T3 PL11188494T PL11188494T PL2591798T3 PL 2591798 T3 PL2591798 T3 PL 2591798T3 PL 11188494 T PL11188494 T PL 11188494T PL 11188494 T PL11188494 T PL 11188494T PL 2591798 T3 PL2591798 T3 PL 2591798T3
Authority
PL
Poland
Prior art keywords
vaccine
tumor immunotherapy
immunotherapy
tumor
Prior art date
Application number
PL11188494T
Other languages
English (en)
Inventor
Werner Lubitz
Pavol Kudela
Jaroslav Michalek
Original Assignee
Werner Lubitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Werner Lubitz filed Critical Werner Lubitz
Publication of PL2591798T3 publication Critical patent/PL2591798T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/456—Escherichia; Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
PL11188494T 2011-11-09 2011-11-09 Szczepionka do zastosowania w immunoterapii nowotworów PL2591798T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11188494.6A EP2591798B1 (en) 2011-11-09 2011-11-09 Vaccine for use in tumor immunotherapy

Publications (1)

Publication Number Publication Date
PL2591798T3 true PL2591798T3 (pl) 2015-04-30

Family

ID=44992693

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11188494T PL2591798T3 (pl) 2011-11-09 2011-11-09 Szczepionka do zastosowania w immunoterapii nowotworów

Country Status (9)

Country Link
US (1) US9790260B2 (pl)
EP (2) EP2591798B1 (pl)
JP (1) JP6029677B2 (pl)
CN (1) CN104066443A (pl)
AU (1) AU2012334095B2 (pl)
ES (1) ES2525205T3 (pl)
HK (1) HK1202070A1 (pl)
PL (1) PL2591798T3 (pl)
WO (1) WO2013068406A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
US20160129097A1 (en) * 2014-11-06 2016-05-12 Jeremy Delk Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit
CN104606665A (zh) * 2015-02-13 2015-05-13 闫书印 一种基于骨髓穿刺术的用于骨转移疼痛的治疗配方
CN105126094A (zh) * 2015-08-13 2015-12-09 安徽农业大学 一种拟态弧菌菌影疫苗及其制备方法和应用
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
US12491153B2 (en) * 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117125A (en) 1977-06-24 1978-09-26 Smithkline Corporation 7-Acylamino-3-[1-[2-(carboxymethylamino]ethyl) tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids
DE19732829A1 (de) 1997-07-30 1999-02-04 Lubitz Werner Prof Dr Sekretion von trägergebundenen Proteinen in das Periplasma und in den extrazellulären Raum
DE19909770A1 (de) * 1999-03-05 2000-09-07 Werner Lubitz Bakterienghosts als Träger- und Targetingvehikel
DE10003241A1 (de) 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US7037500B1 (en) * 2000-09-08 2006-05-02 The Trustees Of Columbia University In The City Of New York Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity
CA2453518C (en) 2001-07-11 2010-02-02 Werner Lubitz Nucleic acid-free bacterial ghost preparation formed by co-expression of lytic and nuclease genes
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
ES2401706T3 (es) 2005-07-27 2013-04-23 Eli Lilly And Company Un método de tratar células cancerosas para crear una célula cancerosa modificada que provoca una respuesta inmunogénica
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
US20080031900A1 (en) 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
EP1897557A1 (en) * 2006-09-07 2008-03-12 Helmholtz-Zentrum für Infektionsforschung GmbH Use of glycolipids as adjuvants
NZ586669A (en) 2008-01-18 2012-06-29 Werner Lubitz Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법

Also Published As

Publication number Publication date
JP6029677B2 (ja) 2016-11-24
AU2012334095A1 (en) 2014-05-29
WO2013068406A1 (en) 2013-05-16
CN104066443A (zh) 2014-09-24
US9790260B2 (en) 2017-10-17
EP2591798A1 (en) 2013-05-15
EP2591798B1 (en) 2014-11-19
HK1202070A1 (zh) 2015-09-18
EP2776060A1 (en) 2014-09-17
ES2525205T3 (es) 2014-12-18
US20130115245A1 (en) 2013-05-09
JP2015504423A (ja) 2015-02-12
AU2012334095B2 (en) 2017-10-12
NZ624069A (en) 2015-10-30

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
SG11201400432VA (en) Polypeptide vaccine
IL231043A (en) vaccine
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
GB201120860D0 (en) Cancer immunotherapy
SG11201401632WA (en) Antigen presenting cancer vaccine
GB201119999D0 (en) Vaccine
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
ZA201402071B (en) Vaccine therapy
SMT201900521T1 (it) Vaccini individualizzati per il cancro
GB201120000D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201108984D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108982D0 (en) Vaccines
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
IL229242A0 (en) Allogeneic cell vaccine for cancer